Sight Sciences, Inc. (NASDAQ:SGHT) COO Sells $21,890.25 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) COO Sam Boong Park sold 3,525 shares of the company’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $6.21, for a total transaction of $21,890.25. Following the sale, the chief operating officer now owns 258,229 shares in the company, valued at $1,603,602.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Sight Sciences Stock Performance

Shares of SGHT stock opened at $6.19 on Friday. The stock’s 50-day moving average is $6.09 and its two-hundred day moving average is $5.26. The company has a quick ratio of 12.42, a current ratio of 13.01 and a debt-to-equity ratio of 0.31. Sight Sciences, Inc. has a 1 year low of $1.04 and a 1 year high of $9.31.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). The firm had revenue of $19.27 million for the quarter, compared to analysts’ expectations of $18.34 million. Sight Sciences had a negative return on equity of 44.45% and a negative net margin of 67.18%. As a group, sell-side analysts forecast that Sight Sciences, Inc. will post -1.13 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on SGHT. Piper Sandler reissued a “neutral” rating and issued a $6.00 price objective (up from $5.00) on shares of Sight Sciences in a research report on Friday, May 3rd. Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a research note on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, Sight Sciences has a consensus rating of “Hold” and an average target price of $4.70.

Hedge Funds Weigh In On Sight Sciences

A number of hedge funds have recently modified their holdings of SGHT. Tower Research Capital LLC TRC boosted its stake in Sight Sciences by 180.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 12,076 shares of the company’s stock worth $62,000 after purchasing an additional 7,764 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Sight Sciences by 51.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock valued at $141,000 after buying an additional 9,106 shares during the last quarter. State Board of Administration of Florida Retirement System acquired a new stake in shares of Sight Sciences during the first quarter worth about $59,000. Federated Hermes Inc. grew its holdings in shares of Sight Sciences by 100.0% during the third quarter. Federated Hermes Inc. now owns 60,000 shares of the company’s stock worth $202,000 after buying an additional 30,000 shares during the last quarter. Finally, Panagora Asset Management Inc. increased its position in Sight Sciences by 198.1% in the 4th quarter. Panagora Asset Management Inc. now owns 59,190 shares of the company’s stock valued at $305,000 after acquiring an additional 39,333 shares during the period. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.